Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus

PLoS Pathog. 2018 Jun 21;14(6):e1007124. doi: 10.1371/journal.ppat.1007124. eCollection 2018 Jun.

Abstract

Hepatitis B virus (HBV) is one of the major etiological pathogens for liver cirrhosis and hepatocellular carcinoma. Chronic HBV infection is a key factor in these severe liver diseases. During infection, HBV forms a nuclear viral episome in the form of covalently closed circular DNA (cccDNA). Current therapies are not able to efficiently eliminate cccDNA from infected hepatocytes. cccDNA is a master template for viral replication that is formed by the conversion of its precursor, relaxed circular DNA (rcDNA). However, the host factors critical for cccDNA formation remain to be determined. Here, we assessed whether one potential host factor, flap structure-specific endonuclease 1 (FEN1), is involved in cleavage of the flap-like structure in rcDNA. In a cell culture HBV model (Hep38.7-Tet), expression and activity of FEN1 were reduced by siRNA, shRNA, CRISPR/Cas9-mediated genome editing, and a FEN1 inhibitor. These reductions in FEN1 expression and activity did not affect nucleocapsid DNA (NC-DNA) production, but did reduce cccDNA levels in Hep38.7-Tet cells. Exogenous overexpression of wild-type FEN1 rescued the reduced cccDNA production in FEN1-depleted Hep38.7-Tet cells. Anti-FEN1 immunoprecipitation revealed the binding of FEN1 to HBV DNA. An in vitro FEN activity assay demonstrated cleavage of 5'-flap from a synthesized HBV DNA substrate. Furthermore, cccDNA was generated in vitro when purified rcDNA was incubated with recombinant FEN1, DNA polymerase, and DNA ligase. Importantly, FEN1 was required for the in vitro cccDNA formation assay. These results demonstrate that FEN1 is involved in HBV cccDNA formation in cell culture system, and that FEN1, DNA polymerase, and ligase activities are sufficient to convert rcDNA into cccDNA in vitro.

MeSH terms

  • DNA, Circular / genetics
  • DNA, Circular / metabolism*
  • DNA, Viral / genetics
  • DNA, Viral / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Flap Endonucleases / antagonists & inhibitors
  • Flap Endonucleases / genetics
  • Flap Endonucleases / metabolism*
  • Hep G2 Cells
  • Hepatitis B / enzymology
  • Hepatitis B / genetics*
  • Hepatitis B / virology
  • Hepatitis B virus / genetics*
  • Hepatocytes / drug effects
  • Hepatocytes / metabolism
  • Hepatocytes / virology
  • Humans
  • Virion / enzymology
  • Virion / genetics*
  • Virus Replication

Substances

  • DNA, Circular
  • DNA, Viral
  • Enzyme Inhibitors
  • Flap Endonucleases
  • FEN1 protein, human

Grants and funding

This study was supported by the Funding Program for Next Generation World-Leading Researchers (LS051 to MM) http://www.jsps.go.jp/english/e-jisedai/index.html; a Grant-in-Aid for Scientific Research B (26293103 to MM) and C (26460993 to KK) from the Japan Society for the Promotion of Science http://www.jsps.go.jp/english/e-grants/index.html; the Ministry of Health, Labour and Welfare of Japan (H26-kanen jitsuyouka-wakate008 to KK) http://www.mhlw.go.jp/english/; Program on the Innovative Development and the Application of New Drugs for Hepatitis B from Japan Agency for Medical Research and Development, AMED (JP18fk0310119h0002 to KK) http://www.amed.go.jp/en/;the Takeda Science Foundation (to MM and KK) http://www.takeda-sci.or.jp/index.html; and the Association for Research on Lactic Acid Bacteria (to MM) https://institute.yakult.co.jp/en/; the GSK Japan Research Grant 2016 (to KK) https://jp.gsk.com/jp/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.